Plumbline Life Sciences, Inc.

A222670

KR7222670002

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
6,040 ^KRW	-0.33%		+0.83%	0.00%

2023	Plumbline Life Sciences, Inc. announced that it has received KRW 500.12 million in funding	CI
2023	Plumbline Life Sciences, Inc. announced that it expects to receive KRW 500.12 million in funding	CI

Plumbline Life Sciences, Inc. announced that it has received KRW 740 million in funding

January 03, 2022

On January 4, 2022, Plumbline Life Sciences, Inc. closed the transaction. The company has received KRW 340,000,000 through issuance of preferred shares bringing total proceeds to KRW 740,000,000.

Latest news about Plumbline Life Sciences, Inc.

Plumbline Life Sciences, Inc. announced that it has received KRW 500.12 million in funding	23-10-23	CI
Plumbline Life Sciences, Inc. announced that it expects to receive KRW 500.12 million in funding	23-10-22	CI
Plumbline Life Sciences, Inc. announced that it expects to receive KRW 500.12 million in funding	23-10-22	CI
Plumbline Life Sciences, Inc. announced that it has received KRW 599.994 million in funding	23-07-13	CI
Plumbline Life Sciences, Inc. announced that it expects to receive KRW 599.994 million in funding	23-07-02	CI
Plumbline Life Sciences, Inc. announced that it has received KRW 50 million in funding	23-04-06	CI
Plumbline Life Sciences, Inc. announced that it expects to receive KRW 50 million in funding	23-04-05	CI
Plumbline Life Sciences, Inc. announced that it has received KRW 100 million in funding	22-09-06	CI
Plumbline Life Sciences, Inc. announced that it expects to receive KRW 100 million in funding	22-09-05	CI
Plumbline Life Sciences, Inc. announced that it has received KRW 110 million in funding	22-02-09	CI
Plumbline Life Sciences, Inc. announced that it expects to receive KRW 110 million in funding	22-01-26	CI
Plumbline Life Sciences, Inc. announced that it has received KRW 740 million in funding	22-01-03	CI
Plumbline Life Sciences, Inc. announced that it expects to receive KRW 740 million in funding	21-12-26	CI
Plumbline Life Sciences, Inc. announced that it has received KRW 1.2606 billion in funding	21-08-26	CI
Plumbline Life Sciences, Inc. announced that it expects to receive KRW 1.2606 billion in funding	21-08-18	CI
Plumbline Life Sciences, Inc. announced that it has received KRW 1.1 billion in funding from DADAM Investment Corp.	20-12-03	CI
Plumbline Life Sciences, Inc. announced that it expects to receive KRW 1.1 billion in funding from DADAM Investment Corp.	20-11-22	CI
Plumbline Life Sciences, Inc. announced that it has received KRW 45 billion in funding	19-08-15	CI
Plumbline Life Sciences, Inc. announced that it expects to receive KRW 45 billion in funding	19-08-07	CI
Inovio Pharmaceuticals Inc. and Plumbline Life Sciences Establish Animal Health Collaboration to Develop a Novel Vaccine Against Deadly African Swine Fever Virus	19-05-15	CI
Plumbline Life Sciences, Inc. announced that it has received KRW 1 billion in funding	19-03-21	CI
Plumbline Life Sciences, Inc. announced that it expects to receive KRW 1 billion in funding	19-03-13	CI
Apiam Animal Health Limited Enters into a Distribution Agreement with Plumbline Life Sciences	18-07-18	CI
Plumbline Life Sciences, Inc. announced that it has received KRW 635 million in funding	17-07-12	CI
Plumbline Life Sciences, USA, Inc. announced that it has received funding from Plumbline Life Sciences, Inc.	16-03-02	CI

Chart Plumbline Life Sciences, Inc.

Duration

Period

More charts

Plumbline Life Sciences, Inc. is a Korea-based company mainly engaged in the research and development, manufacture and distribution of bio pharmaceuticals for animals using gene therapy. The Company provides small animal personalized medicines, infectious vaccines, growth hormone releasing hormone (GHRH), telomerase reverse transcriptase (TERT) and others. The Companyâs products are mainly used for pigs, cats, dogs, cows, horses and other animals.

Sector

Pharmaceuticals

More about the company

Sector Biopharmaceuticals

	1st Jan change	Capi.
PLUMBLINE LIFE SCIENCES, INC.	0.00%	12.38M
CSL LIMITED	-4.66%	86.13B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	39.82B
BIOGEN INC.	-19.27%	30.42B
UCB	+57.86%	25.23B
INCYTE CORPORATION	-17.69%	11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.00%	11.51B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.14%	11.95B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	8.71B
INNOVENT BIOLOGICS, INC.	-8.42%	8.12B

Biopharmaceuticals